SGLT1/2 (dual)

Class

Dual sodium-glucose cotransporter 1/2 inhibitor

Sodium-glucose cotransporters (SGLTs) are membrane proteins that move glucose across cell membranes together with sodium, using the sodium gradient as an energy source. SGLT2, found mainly in the kidney's proximal tubule, is responsible for reclaiming most of the glucose filtered by the glomerulus back into the bloodstream. SGLT1 performs a related role in the kidney (recovering the residual filtered glucose) and, separately, in the intestinal lining, where it absorbs dietary glucose and galactose into circulation. Inhibiting SGLT2 alone lowers blood glucose by allowing more glucose to pass into the urine, an approach used broadly in type 2 diabetes. A dual SGLT1/2 inhibitor extends this by also blocking intestinal SGLT1, which slows and reduces the absorption of glucose from meals, blunting the rise in blood sugar that follows eating. This combined action addresses both the fasting and post-meal components of hyperglycemia through a single pathway, sodium-coupled glucose transport, rather than through hormonal signaling. The rationale for pursuing dual rather than SGLT2-selective inhibition is to achieve broader glycemic control by acting at two anatomically distinct but mechanistically related sites, relevant to diabetes management and, more speculatively, to metabolic and cardiorenal conditions where glucose handling contributes to disease burden.